Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Patent
1996-07-12
2000-03-07
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
424424, 424436, 424448, 424451, 424464, 514654, A61K 900, A61K 908, A61K 920, A61K 948
Patent
active
06033682&
ABSTRACT:
The present invention provides novel compositions and methods for using the S(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
REFERENCES:
patent: 4564706 (1986-01-01), Ecsery et al.
patent: 4812481 (1989-03-01), Reischig et al.
patent: 4861800 (1989-08-01), Buyske
patent: 4925878 (1990-05-01), Bodo et al.
patent: 5075338 (1991-12-01), Knoll et al.
patent: 5128145 (1992-07-01), Edgren et al.
patent: 5190763 (1993-03-01), Edgren et al.
patent: 5225446 (1993-07-01), Milgram
patent: 5234957 (1993-08-01), Mantelle
patent: 5242950 (1993-09-01), Fries Hastings
patent: 5380761 (1995-01-01), Szabo et al.
Amenta et al., "Microanatomical Changes in the Frontal Cortex of Aged Rats: Effect of L-Deprenyl Treatment," Brain Res. Bull. 34:125-131 (1994).
Ansari et al., "Rescue of Axotomized Immature Rat Facial Motoneurons by R(-)-Deprenyl: Stereospecificity and Independence from Monoamine Oxidase Inhibition," J. Neurosci. 13(9):4042-4053 (1993).
Berry et al., "Possible Mechanisms of Action of (-)Deprenyl and Other MAO-B Inhibitors in Some Neurologic and Psychiatric Disorders," Prog. in Neurobiol. 44:141-161 (1994).
Casper et al., "EGF Enhances the Survival of Dopamine Neurons in Rat Embryonic Mesencephalon Primary Cell Culture," J. Neurosci. Res. 30:372-381 (1991).
Glover et al., "Neurotoxins and Monoamine Oxidase B Inhibitors: Possible Mechanisms for the Neuroprotective Effect of (-)-Deprenyl," Inhibitors of Monoamine Oxidase B, Chapter 8 (1993).
Iwasaki et al., "Deprenyl Enhances Neurite Outgrowth in Cultured Rat Spinal Ventral Horn Neurons," J. Neurol Sci. 125:11-13 (1994).
Ju et al., "(-)-Deprenyl Alters the Time Course of Death of Axotomized Facial Motoneurons and the Hypertrophy of Neighoring Astrocytes in Immature Rats," Exp. Neurol. 126:233-246 (1994).
Matsui et al., "Monoamine Oxidase Inhibitors Prevent Striatal Neuronal Necrosis Induced by Transient Forebrain Ischemia," Neurosci. Lett. 126:175-178 (1991).
Park et al., "Protection from 1-Methyl-4-Phenylpyridinium (MPP.sup.+) Toxicity and Stimulation of Regrowth of MPP.sup.+ -damaged Dopaminergic Fibers by Treatment of Mesencephalic Cultures with EGF and Basic FGF," Brain Res. 599:83-97 (1992).
Rinne, "Nigral Degeneration in Parkinson's Disease in Relation to Clinical Features," Acta Neurol. Scand. 84(supp. 136):87-90 (1991).
Rinne et al., "Selegiline (Deprenyl) Treatment and Death of Nigral Neurons in Parkinson's Disease," Neurology 41:859-861 (1991).
Salo et al., "Deprenyl Reduces the Death of Motoneurons Caused by Axotomy," J. Neurosci. Res. 31:394-400 (1992).
Tatton, "Selegiline Can Mediate Neuronal Rescue Rather Than Neuronal Protection," Movement Disorders 8:520-530 (1993).
Tatton et al., "`Trophic-Like` Actions of (-)-Deprenyl on Neurons and Astroglia," in Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction 7:238-248 (1994).
Zeng et al., "Influence of Long-Term Treatment with L-Deprenyl on the Age-Dependent Changes in Rat Brain Microanatomy," Mech. Ageing Dev. 73:113-126 (1994).
Borbe et al., "Kinetic Evaluation of MAO-B-Activity Following Oral Administration of Selegiline and Desmethyl-Selegiline in the Rat," J. Neural. Transm. 32:131-137 (1990).
Gershon et al., "Monoamine Oxidase Inhibition and the Induction of Ponto-Geniculo-Occipital Wave Activity by Reserpine in the Cat," J. Pharmacol. Exp. Ther. 197:556-566 (1976).
Heinonen et al., "Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of MAO-B in Human Subjects," Neurology 43:A156 (1993).
Heinonen et al., "Pharmacokinetic Aspects of l-Deprenyl (Selegiline) and Its Metabolites," Clin. Pharmacol. Ther. 56:742-749 (1994).
Heinonen et al., "Pharmacokinetics and Metabolism of Selegiline," Acta. Neurol. Scand. 126:93-99 (1989).
Martin et al., "Regression Analysis of the Relationship between Physical Properties and the in Vitro Inhibition of Monoamine Oxidase by Propynylamines," J. Med. Chem. 18:883-888 (1975).
Nickel et al., "Effect of Selegiline and Desmethyl-Selegiline on Cortical Electric Activity in Rats," J. Neural. Transm. 32:139-144 (1990).
Williams et al., "Biochemical and Behavioural Studies of Monoamine Oxidase Inhibition," Ir. J. Med. Sci. 147:71-74 (1978).
Channavajjala L.
Page Thurman K.
Sanzo Michael A.
Somerset Pharmaceuticals, Inc.
LandOfFree
S(+) desmethylselegiline and its use in therapeutic methods and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with S(+) desmethylselegiline and its use in therapeutic methods and , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S(+) desmethylselegiline and its use in therapeutic methods and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-360353